国产多西他赛周剂量治疗晚期老年非小细胞肺癌临床观察

Observation of Weekly Domestic Docetaxel in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

目的观察周剂量多西他赛治疗老年晚期非小细胞肺癌患者的临床疗效。方法32例老年晚期非小细胞肺癌患者予以国产多西他赛40mg/m2,静脉滴注3h,第1,8,15天给药,每28天为1周期。完成2周期后评价疗效,有效及稳定病例完成4周期,随访至疾病进展和患者死亡。结果30例评价病例中,总有效率为35.7%,疾病控制率为65.5%,中位生存期11.8月,一年生存率40%。全组患者的性别、ECOF评分两项指标在治疗后的中位生存期方面差异有显著性(P<0.05),不良反应以粒细胞减少、乏力、脱发为主。结论国产多西他赛周剂量治疗晚期老年非小细胞肺癌显示了较好的疗效,患者的耐受性较好。

Objective To observe the efficacy of weekly domestic docetaxel in elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods 32 elderly patients with advanced NSCLC who were chemotherapye were treated with domestic docetaxel at the dose of 40mg/m^2 on day 1,8,15d every 28 days. Re-evaluated was done after two cycles. Those who did not get progressed went through another two cycles of chemotherapy and all patients were followed up until disease progressed or patients died. Results 30 patients were evaluated with 35.7% response rate, 65.5% stable disease, 3.4 months of median progression free survival（PFS）, 11.8 months of median OS and 40% 1-year survival rate. There was statistical significance only in different gender and performance status in terms of overall survival （P 〈 0.05）. The common adverse events were neutropenia, aneamia, shed-hair. Conclusion Weekly domestic docetaxel is effective in the treatment of elderly patients with advanced NSCLC and patients tolerate well.